摘要
目的探究重组组织型纤溶酶原激活剂静脉溶栓在急性脑梗死治疗中的应用价值。方法研究对象选自该院收治的急性脑梗死患者,时间为2017年1月—2019年12月,共计46例。按照随机数字表法分为常规治疗的对照组和重组组织型纤溶酶原激活剂静脉溶栓(rt-PA)治疗的观察组,应用NHISS量表评估两组患者治疗前、治疗后1 d和14 d的神经功能缺损症状评分,观察记录两组患者出现的并发症,分析临床应用效果。结果对照组治疗前NHSS评分为(11.32±1.19)分,观察组治疗前NIHSS评分为(11.24±1.30)分,两组数据差异无统计学意义(t=0.218,P>0.05);对照组治疗后1 d和治疗后14 d NIHSS评分分别为(10.55±0.84)分、(10.90±0.91)分,观察组治疗后1 d和治疗后14 d NIHSS评分分别为(8.61±0.83)分、(7.41±0.85)分,观察组明显低于对照组,且差异有统计学意义(t=7.879、13.441,P<0.05);与对照组(39.13%)相比,观察组并发症发生率(13.04%)明显更低,差异有统计学意义(χ~2=4.059,P<0.05)。结论重组组织型纤溶酶原激活剂静脉溶栓用于急性脑梗死患者的治疗时,可有效改善自身神经功能缺损,降低并发症发生风险,是临床切实可行的治疗方法,值得推广应用。
Objective To explore the application value of recombinant tissue plasminogen activator intravenous thrombolysis in the treatment of acute cerebral infarction.Methods The research subjects were selected from patients with acute cerebral infarction admitted in the hospital from January 2017 to December 2019,a total of 46 cases.According to the random number table method,it was divided into a conventionally treated control group and an observation group treated with recombinant tissue-type plasminogen activator intravenous thrombolysis(rt-PA).The NHISS scale was used to evaluate the two groups of patients before treatment and 1 d after treatment and the 14 d neurological deficit symptom score,observe and record the complications of the two groups of patients,and analyze the clinical application effect.Results The NHSS score of the control group before treatment was(11.32±1.19)points,the NIHSS score of the observation group before treatment was(11.24±1.30)points,the two groups of data were not statistically significant difference(t=0.218,P>0.05);the control group of the NIHSS scores were(10.55±0.84)points and(10.90±0.91)points 1 d after treatment and 14 d after treatment of the NIHSS scores of the observation group were(8.61±0.83)points after treatment and 14 d after treatment,and(7.41±0.85)points,the observation group was significantly lower than the control group,and the difference was statistically significant(t=7.879,13.441,P<0.05);compared with the control group(39.13%),the incidence of complications in the observation group(13.04%)was significantly lower,the difference was statistically significant(χ~2=4.059,P<0.05).Conclusion Recombinant tissue-type plasminogen activator intravenous thrombolysis used in the treatment of patients with acute cerebral infarction can effectively improve its own neurological deficits and reduce the risk of complications.It is a clinically feasible treatment method and is worthy of popularization and application.
作者
刘晓巧
潘阔
LIU Xiao-qiao;PAN Kuo(Department of Neurology,Guanyun County People's Hospital,Lianyungang,Jiangsu Province,222200 China;Department of Critical Care Medicine,Guanyun County People's Hospital,Lianyungang,Jiangsu Province,222200 China)
出处
《系统医学》
2020年第13期49-51,共3页
Systems Medicine
关键词
重组组织型纤溶酶原激活剂
静脉溶栓
急性脑梗死
临床应用价值
Recombinant tissue plasminogen activator
Intravenous thrombolysis
Acute cerebral infarction
Clinical value
作者简介
刘晓巧(1987-),女,回族,山西临汾人,本科,主治医师,主要从事常见脑血管疾病诊断工作;通讯作者:潘阔(1987-),男,江苏灌云人,本科,主治医师,研究方向:血液净化,E-mail:272097262@qq.com。
